Fig. 2. LUM015 fluorescently labels tumor cells in mouse models of STS and breast cancer. LUM015 fluorescently labels tumor cells in mouse models of STS.

Slides:

Advertisements

Similar presentations

Fig. 2. LUM015 fluorescently labels tumor cells in mouse models of STS and breast cancer. LUM015 fluorescently labels tumor cells in mouse models of STS.

Advertisements

Fig. 1. Potent and selective down-regulation of KRAS mRNA and protein by AZD4785 in vitro and in vivo. Potent and selective down-regulation of KRAS mRNA.

Fig. 1 Localized treatment of TNBC cancers kills tumor cells and minimizes the metastatic burden. Localized treatment of TNBC cancers kills tumor cells.

Fig. 8. In vivo suppression of MM by CMLD

Fig. 3. Paclitaxel promotes TMEM-dependent vascular permeability, cancer cell dissemination, and metastasis in breast cancer. Paclitaxel promotes TMEM-dependent.

Fig. 1. Paclitaxel delays tumor growth and promotes infiltration of TIE2hi/VEGFhi macrophages and TMEM assembly. Paclitaxel delays tumor growth and promotes.

Expression of CD36 and psap in a TMA of human ovarian cancer patients

Fig. 3. Wisper controls CF behavior and survival.

Fig. 4. Antitumor efficacy of ERY974 against various cancer types.

Fig. 5 Combination intravenous reovirus and checkpoint inhibition in an orthotopic syngeneic brain tumor model. Combination intravenous reovirus and checkpoint.

Antitumor effect of local cancer immunotherapy treatment toward distant B16F10 tumors. Antitumor effect of local cancer immunotherapy treatment toward.

Role of immune and inflammatory cells in lung cancer–associated PH

Fig. 5 Local gel scaffold for T cell memory response.

Fig. 3 Agonists of innate immunity are effective only when released locally from the hydrogel. Agonists of innate immunity are effective only when released.

Fig. 4. Dabrafenib and trametinib changed the cellular components of the tumor microenvironment. Dabrafenib and trametinib changed the cellular components.

Selection of a 4-1BB-endodomain–based anti-EGFRvIII CAR construct

Fig. 5 Hypoxic tumors from obese mice associate with increased production of IL-6 by adipocytes and myeloid cells. Hypoxic tumors from obese mice associate.

Fig. 1. Schematic showing the shedding of tumor DNA from head and neck cancers into the saliva or plasma. Schematic showing the shedding of tumor DNA from.

Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.

Fig. 4. The effect of combined inhibition of BCL-2 and BCR-ABL on leukemia LT-HSC frequency. The effect of combined inhibition of BCL-2 and BCR-ABL on.

Fig. 6. Nontaxane chemotherapies induce TMEM-dependent prometastatic changes in the breast cancer microenvironment. Nontaxane chemotherapies induce TMEM-dependent.

Genetic EGFR ablation in K-RAS–mutated lung AC reduces tumor growth

Vaccine MN confer protective innate and adaptive immunity.

Fig. 3 NK cells are enriched in ICB-sensitive tumors in mouse models and patients and are required for response. NK cells are enriched in ICB-sensitive.

Fig. 2 LYM attractor metagene.

Fig. 5. Col IV–Ac2-26 NPs decrease lesion area, necrotic area, and oxidative stress in brachiocephalic arterial plaques. Col IV–Ac2-26 NPs decrease lesion.

Colonization in tumor models and different modes of administration

Fig. 1. Potent and selective down-regulation of KRAS mRNA and protein by AZD4785 in vitro and in vivo. Potent and selective down-regulation of KRAS mRNA.

Fig. 4 Rational therapeutic modulation of the tumor microenvironment sensitizes tumors to ICB. Rational therapeutic modulation of the tumor microenvironment.

Fig. 2 Inflammatory pathways with STAT1 as a key regulator are enriched in ICB responsive tumors in mouse models and patients. Inflammatory pathways with.

Fig. 1. DEL-1 is expressed by human and mouse osteoclasts.

Fig. 5 Treatment with BMS (PO BID) protects from wasting and colitis in two SCID mouse models. Treatment with BMS (PO BID) protects from.

The microchip-based drug delivery device and overview of study design

Fig. 7. CIVO performance in canine lymphoma tumors demonstrates spatially restricted responses linked to drug mechanism. CIVO performance in canine lymphoma.

Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model in vivo. Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model.

Fig. 2 Extended local release of agonists of innate immunity prevents tumor recurrence and eliminates distal metastases. Extended local release of agonists.

Fig. 1. Matrix stiffness sensitizes myofibroblasts to apoptosis induced by inhibition of their mechanotransduction pathways. Matrix stiffness sensitizes.

Fig. 4. Paclitaxel promotes the expression of invasive isoforms of MENA in the primary breast cancer microenvironment. Paclitaxel promotes the expression.

PD and efficacy of AZD4785 in KRAS mutant lung cancer xenograft models

Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice by Gabrielle Fredman,

MEDI4736 shows antitumor activity in xenograft mouse models of human cancer. MEDI4736 shows antitumor activity in xenograft mouse models of human cancer.

Fig. 6. Microglial phagocytosis and lysosomal uptake of Aβ induced by SUS treatment. Microglial phagocytosis and lysosomal uptake of Aβ induced by SUS.

Example inverse FF-OCT images (left column) and corresponding histology images (right column) of ovarian metastases. Example inverse FF-OCT images (left.

Fig. 6 Antitumor effect on tumor growth and pulmonary metastasis of CSSD-9 in vivo. Antitumor effect on tumor growth and pulmonary metastasis of CSSD-9.

Fig. 4. HERV-K env expression and injury to lower motor neurons.

Patrolling monocytes control tumor metastasis to the lung

Delineating cancer evolution with single-cell sequencing

Intraperitoneal or intratumoral injection of 6-thio-dG or 6-thioguanine. Intraperitoneal or intratumoral injection of 6-thio-dG or 6-thioguanine. A, 2.

In vivo prophylactic and therapeutic efficacy of C12G6 in mice

miR can promote cardiomyocyte proliferation in the adult heart

Fig. 2 Increasing KLF17, CDH1, and LASS2 expression reduced malignant progression and promoted apoptosis of tumor cells. Increasing KLF17, CDH1, and LASS2.

Fig. 8. TIE2 inhibitor rebastinib eliminates the prometastatic effects of paclitaxel. TIE2 inhibitor rebastinib eliminates the prometastatic effects of.

Fig. 1. Paclitaxel delays tumor growth and promotes infiltration of TIE2hi/VEGFhi macrophages and TMEM assembly. Paclitaxel delays tumor growth and promotes.

Fig. 5 In vivo autologous self-targeting efficacy of DR-KO tumor cells co-engineered with a secretable DRL and a suicide system. In vivo autologous self-targeting.

Fig. 6. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex.

Fig. 3. Paclitaxel promotes TMEM-dependent vascular permeability, cancer cell dissemination, and metastasis in breast cancer. Paclitaxel promotes TMEM-dependent.

Fig. 3 Superiority of BAFF-R versus CD19-CAR T cells in a Burkitt lymphoma model is not due to greater tumor antigen density. Superiority of BAFF-R versus.

Fig. 2. Col IV–Ac2-26 NPs increase subendothelial collagen in Ldlr−/− mice with established atherosclerosis. Col IV–Ac2-26 NPs increase subendothelial.

Fig. 5 Distributions of cell nuclear area values and internuclear distances in the breast tumor specimens (Figs. 3 and 4), where bin interval = 8 and n.

Fig. 7. Altered morphology after ultrasound but unaltered numbers of microglia in SUS-treated mice. Altered morphology after ultrasound but unaltered numbers.

Fig. 3. Association between peak CTL019 expansion and response.

Fig. 1 Schematic structure of a fluorescently labeled eGLP1-conjugated MALAT1 ASO and internalization of fluorescent eGLP1 and eGLP1-MALAT1-ASO. Schematic.

Fig. 3. Col IV–Ac2-26 NPs suppress lesional superoxide and increase lesional Il10 mRNA in Ldlr−/− mice with established atherosclerosis. Col IV–Ac2-26.

Fig. 3 Minimal treatment of ETL decreases metastatic burden and prolongs survival in the 4T1 breast carcinoma model after tumor resection. Minimal treatment.

SCLC initiated from pulmonary neuroendocrine cells metastasizes without upregulating NFIB. A and B, Mouse models of SCLC. Rb1flox/flox;Trp53flox/flox;p130flox/flox;R26mTmG.

Fig. 6 Pharmacologic alterations of β-AR signaling regulate cardiomyocyte abscission and endowment. Pharmacologic alterations of β-AR signaling regulate.

PD and efficacy of AZD4785 in a KRAS wild-type lung cancer PDX model

Fig. 5. Paclitaxel promotes breast cancer cell dissemination and metastasis in a MENA-dependent manner. Paclitaxel promotes breast cancer cell dissemination.

Fig. 2. SUS reduces Aβ plaques in an AD mouse model.

Fig. 2. In vivo local CD25-targeted NIR-PIT induces regression of treated LL/2-luc tumors. In vivo local CD25-targeted NIR-PIT induces regression of treated.

Presentation transcript:

Fig. 2. LUM015 fluorescently labels tumor cells in mouse models of STS and breast cancer. LUM015 fluorescently labels tumor cells in mouse models of STS and breast cancer. (A and B) Mean measured fluorescence in primary sarcoma (n = 16) (A) or orthotopic breast cancer (n = 23) (B) and muscle. P values determined by unpaired t test. Representative fluorescence images of resected normal muscle and tumors are shown along with corresponding hematoxylin and eosin (H&E) histology. The same contrast scale was applied to both fluorescence images in each pair. Scale bars, 5 mm for fluorescence images; 500 μm for H&E images in (A); 100 μm for H&E images in (B). (C) Representative flow cytometric analysis of resected mouse tumors expressing tumor cell–specific YFP after intravenous administration of phosphate-buffered saline (PBS) or LUM015 (3.5 mg/kg). Of the tumors from mice treated with LUM015, Cy5+ cells (red box, cells with fluorescence >2 × 102) and YFP+ tumor cells (yellow box) were sorted and quantified (nPBS = 2 mice, nLUM015 = 3 mice). In the Cy5+ cells, the proportions of YFP+ tumor cells and CD11b+ tumor–associated macrophages were further quantified (n = 3 mice). P values were determined by unpaired t test. (D) The correlation between residual fluorescence within the sarcoma tumor bed measured before wound closure and local recurrence–free survival in mice. P value determined by log-rank test. Melodi Javid Whitley et al., Sci Transl Med 2016;8:320ra4 Copyright © 2016, American Association for the Advancement of Science